Article thumbnail

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

By Martin Schuler, Ahmad Awada, Philipp Harter, Jean Luc Canon, Kurt Possinger, Marcus Schmidt, Jacques De Grève, Patrick Neven, Luc Dirix, Walter Jonat, Matthias W. Beckmann, Jochen Schütte, Peter A. Fasching, Nina Gottschalk, Tatiana Besse-Hammer, Frank Fleischer, Sven Wind, Martina Uttenreuther-Fischer, Martine Piccart and Nadia Harbeck
Publisher: Springer Nature
Year: 2012
DOI identifier: 10.1007/s10549-012-2126-1
OAI identifier:
Provided by: MUCC (Crossref)
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://link.springer.com/cont... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.